

Corporate-Sponsored Presentations

| Session Time (CST)/ Location | Abstract No./Title/Lead Author | Session Type and Category |
|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Saturday, December 10, 2022 | | |
| Saturday, December 10, 2022 4:00 PM-5:30 PM Oral Presentation: 4:15 PM Rooms 278-282 | 314 / Brentuximab Vedotin SGN35-027 Part B Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN + AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results From the Single-Arm Phase 2 Study (SGN35-027 Part B) Lead Author: Hun Ju Lee | Oral Presentation Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological |
| Saturday, December 10, 2022 5:30 PM-7:30 PM | 2265 / Brentuximab Vedotin HEOR Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States Lead Author: Stefan K. Barta | Poster Presentation Outcomes Research- Lymphoid Malignancies |
| Sunday, December 11, 2022 | | |
| Sunday, December 11, 2022 6:00 PM-8:00 PM | 3596 / Brentuximab Vedotin HEOR Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Stage III/IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Analysis Using a Real-World Database Lead Author: Allison Winter | Poster Presentation Outcomes Research- Lymphoid Malignancies |
| Monday, December 12, 2022 | | |
| Monday, December 12, 2022 6:00 PM-8:00 PM | 4230 / Brentuximab Vedotin SGN35-027 Part C Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN + AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results From the Single-Arm Phase 2 Study (SGN35-027 Part C) Lead Author: Hun Ju Lee | Poster Presentation Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological |
| Monday, December 12, 2022 6:00 PM-8:00 PM | 4850 / Brentuximab Vedotin HEOR Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients With Hematological Malignancies in the United States (US) Lead Author: Mayur Narkhede | Poster Presentation Health Services and Quality-Lymphoid Malignancies |
| Monday, December 12, 2022 6:00 PM-8:00 PM | 4846 / Brentuximab Vedotin HEOR 10-Year Impact on Productivity Costs Associated With Mortality in Stage III or IV Classical Hodgkin Lymphoma Based on the Overall Survival Update of the ECHELON-1 Trial: Application of an Oncology Simulation Model in the United States Lead Author: Tycel J. Phillips | Poster Presentation Health Services and Quality-Lymphoid Malignancies |
| Monday, December 12, 2022 6:00 PM-8:00 PM | 4562 / SEA-BCMA SGN-BCMA001 SEA-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001) Lead Author: James E. Hoffman | Poster Presentation Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials |

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

IST Presentations

| Session Time (CDT)/ Location | Abstract #/Title/Lead Author | Session Type and Category |
|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Sunday, December 11, 2022 | | |
| Sunday, December 11, 2022 6:00 PM-8:00 PM | 2914 / Brentuximab Vedotin AHOD1331 Peripheral Neuropathy in Children With High-Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children's Oncology Group (COG) AHOD1331 Study Lead Author: Susan Parsons, Frank Keller | Poster Presentation Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological |
| Sunday, December 11, 2022 6:00 PM-8:00 PM | 2921 / Brentuximab Vedotin AHOD1331 Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331 Lead Author: Cindy Schwartz | Poster Presentation Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological |
| Sunday, December 11, 2022 6:00 PM-8:00 PM | 2911 / Brentuximab Vedotin SGN35-IST-033 A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T Cell Lymphoma Lead Author: Stefan K. Barta | Poster Presentation Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological |
| Monday, December 12, 2022 | | |
| Monday, December 12, 2022 10:30 AM-12:00 PM Oral Presentation: 10:45 AM Rooms 265-268 | 728 / Brentuximab Vedotin SGN35-IST-040 Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed by Nivolumab Consolidation in Patients With Limited Stage Hodgkin Lymphoma Lead Author: Steven I. Park | Oral Presentation Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological |
| Monday, December 12, 2022 10:30 AM-12:00 PM Oral Presentation: 11:15 AM Rooms 265-268 | 730 / Brentuximab Vedotin SGN35-IST-018 Brentuximab Vedotin Combined With Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up With Evaluation of Baseline Metabolic Tumor Volume and PET2 Lead Author: Robert Stuver | Oral Presentation Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological |
| Monday, December 12, 2022 6:00 PM-8:00 PM | 4239 / Brentuximab Vedotin SGN35-IST-041 Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma Lead Author: Swetha Kambhampati | Poster Presentation Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological |

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.